These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Quantitation of in vivo growth of plasmacytoma X5563 by immunoassay for its paraprotein with individual antigenic specificity. Yutoku M; Seno H; Watanabe S; Matsuoka Y; Kitagawa M J Natl Cancer Inst; 1972 Nov; 49(5):1395-402. PubMed ID: 4119497 [No Abstract] [Full Text] [Related]
5. Anti-idiotypic response of BALB/c mice to a myeloma protein of BALB/c origin. Tungkanak R; Sirisinha S Proc Soc Exp Biol Med; 1978 Nov; 159(2):176-9. PubMed ID: 714942 [No Abstract] [Full Text] [Related]
6. Tumor-associated transplantation antigens of myelomas induced in BALB-c mice. Williams WH; Krueger RG J Natl Cancer Inst; 1972 Dec; 49(6):1613-20. PubMed ID: 4119165 [No Abstract] [Full Text] [Related]
7. Cellular and viral antigens of BALB-c myeloma. Krueger RG; Williams WH; Miller GC J Natl Cancer Inst; 1974 Apr; 52(4):1203-10. PubMed ID: 4133200 [No Abstract] [Full Text] [Related]
8. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice. Teller MN; Faanes RB Cancer Res; 1980 Aug; 40(8 Pt 1):2790-5. PubMed ID: 6966969 [No Abstract] [Full Text] [Related]
9. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. Freedman PM; Autry JR; Tokuda S; Williams RC J Natl Cancer Inst; 1976 Apr; 56(4):735-40. PubMed ID: 56452 [TBL] [Abstract][Full Text] [Related]
10. Suppression and enhancement of allografted tumour. Yutoku M; Seno H; Matsuoka Y; Kitagawa M Immunology; 1974 Mar; 26(3):623-37. PubMed ID: 4854531 [TBL] [Abstract][Full Text] [Related]
11. Passive immunity to murine plasmacytoma by rabbit antiidiotypic antibody to myeloma protein. Chen Y; Yakulis V; Heller P Proc Soc Exp Biol Med; 1976 Jan; 151(1):121-5. PubMed ID: 1250837 [TBL] [Abstract][Full Text] [Related]
12. Cell-mediated immunity in vitro against syngeneic mouse plasma tumour cells. Wagner H; Röllinghoff M Nat New Biol; 1973 Jan; 241(106):53-4. PubMed ID: 4540590 [No Abstract] [Full Text] [Related]
13. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction. Osborne DP; Katz DH J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034 [TBL] [Abstract][Full Text] [Related]
14. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations. Kleinman R; Dray S Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375 [TBL] [Abstract][Full Text] [Related]
15. Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity. Frikke MJ; Bridges SH; Lynch RG J Immunol; 1977 Jun; 118(6):2206-12. PubMed ID: 864258 [No Abstract] [Full Text] [Related]
16. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. Giovarelli M; Comoglio PM; Forni G Br J Cancer; 1976 Sep; 34(3):233-8. PubMed ID: 788762 [TBL] [Abstract][Full Text] [Related]
17. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma. Potter M; Walters JL J Natl Cancer Inst; 1973 Sep; 51(3):875-81. PubMed ID: 4743559 [No Abstract] [Full Text] [Related]
18. In vitro and in vivo alterations of long-term murine plasmacytoma cultures. Sorenson GD; Pettengill OS Arch Intern Med; 1975 Jan; 135(1):114-8. PubMed ID: 1111460 [TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin-producing tumors and myeloma proteins of mice. Potter M Physiol Rev; 1972 Jul; 52(3):631-719. PubMed ID: 4555516 [No Abstract] [Full Text] [Related]